High expression of slc20a1 is less effective for endocrine therapy and predicts late recurrence in er-positive breast cancer

HIGHLIGHTS

• who: Chotaro Onaga and collaborators from the Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of(KA.), JST Moonshot RandD, Saitama, Japan have published the research work: High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer, in the Journal: PLOS ONE of February/17,/2022
• what: The authors examined the possible association of SLC20A1 expression with tumor staging endocrine therapy and chemotherapy in the luminal A and luminal B subtypes of breast cancer. This study analyzed the METABRIC dataset.
•  

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.